Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Globus Medical plans to buy spinal cord stimulation company Nevro for about $250 million, the companies announced on Thursday. Globus will pay $5.85 per share in an all-cash purchase, a 27% ...

The global spinal cord stimulators market is on an accelerated growth path, projected to reach USD 5,441.4 million by 2033 from its current valuation of USD 2,702.7 million in 2023. With a strong ...

"I would like to thank everyone involved in our SENZA-RCT study, especially the investigators, study coordinators, Nevro employees, and most importantly the patients who consented to participate in ...

22, 2015 /PRNewswire/ -- Nevro Corp. (NYSE ... of its Premarket Approval Application (PMA) for the Senza spinal cord stimulation (SCS) system. According to the approvable letter, approval ...

People with spinal muscle atrophy (SMA), an inherited neuromuscular disease, usually experience muscle weakness that impacts movement. New research suggests that electrical spinal cord stimulation ...

First-in-human study of epidural spinal cord stimulation in individuals with spinal muscular atrophy. Nature Medicine , 2025; DOI: 10.1038/s41591-024-03484-8 Cite This Page : ...

Following strong financial results revealed last month, US-headquartered Globus Medical has agreed to acquire spinal cord stimulation (SCS) company Nevro for $250m to reinforce its position in the ...

New research suggests that electrical spinal cord stimulation could improve muscle function for these patients, even restoring the capability to walk. In studies at the University of Pittsburgh School ...